Fuxing Zhao
- Oncology top 5%
- HER2/EGFR in Cancer Research 14
- Cancer Treatment and Pharmacology 10
- Cancer Immunotherapy and Biomarkers 8
-
- Advanced Breast Cancer Therapies 10
- Gastric Cancer Management and Outcomes 7
- Metastasis and carcinoma case studies 6
- Brain Metastases and Treatment 4
-
- Breast Cancer Treatment Studies 15
- Partner nations
- ChinaUnited States
In The Last Decade
Fuxing Zhao
50 papers receiving 940 citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Oncology 542
- Pulmonary and Respiratory Medicine 347
- Cancer Research 151
- Health Informatics 8
- Clinical Biochemistry 28
Countries citing papers authored by Fuxing Zhao
This map shows the geographic impact of Fuxing Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fuxing Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fuxing Zhao more than expected).
Fields of papers citing papers by Fuxing Zhao
This network shows the impact of papers produced by Fuxing Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fuxing Zhao. The network helps show where Fuxing Zhao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fuxing Zhao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 18 | |
| 4 | 2024 | 3 | |
| 5 | 2024 | 9 | |
| 6 | 2024 | 3 | |
| 7 | 2024 | 2 | |
| 8 | 2023 | 8 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 4 | |
| 11 | 2023 | 4 | |
| 12 | 2023 | 6 | |
| 13 | 2023 | 6 | |
| 14 | 2022 | 7 | |
| 15 | 2021 | 13 | |
| 16 | 2021 | 22 | |
| 17 | 2021 | 7 | |
| 18 | 2018 | 5 | |
| 19 | 2018 | 6 | |
| 20 | Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical developmentbreakdown → | 2018 | 446 |
About Fuxing Zhao
Fuxing Zhao is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 56 papers that have together received 948 indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (15 papers), HER2/EGFR in Cancer Research (14 papers), Advanced Breast Cancer Therapies (10 papers), Cancer Treatment and Pharmacology (10 papers), Cancer Immunotherapy and Biomarkers (8 papers), Gastric Cancer Management and Outcomes (7 papers), Metastasis and carcinoma case studies (6 papers) and Brain Metastases and Treatment (4 papers). The work is most often cited by research in Oncology (542 citations), Pulmonary and Respiratory Medicine (347 citations) and Cancer Research (151 citations). Fuxing Zhao has collaborated with scholars based in China and United States. Frequent co-authors include Dengfeng Ren, Jiuda Zhao, Guoshuang Shen, Raees Ahmad, Feng Du, Fangchao Zheng, Qiuxia Dong, Ziyi Wang, Jinming Li and Yong‐Hui Zheng.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.